Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer

Paula Lindholm, Maria Lapela, Kjell Någren, Pertti Lehikoinen, Heikki Minn, Sirkku Jyrkkiö

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2009-Jan
OriginalsprogEngelsk
TidsskriftNuclear Medicine Communications
Vol/bind30
Udgave nummer1
Sider (fra-til)30-6
Antal sider6
ISSN0143-3636
StatusUdgivet - 1. jan. 2009
Udgivet eksterntJa

Fingeraftryk

Western World
Pleura
Myocardium
Lymph Nodes
Hormones
Lung
Skin

Citer dette

Lindholm, P., Lapela, M., Någren, K., Lehikoinen, P., Minn, H., & Jyrkkiö, S. (2009). Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nuclear Medicine Communications, 30(1), 30-6.
Lindholm, Paula ; Lapela, Maria ; Någren, Kjell ; Lehikoinen, Pertti ; Minn, Heikki ; Jyrkkiö, Sirkku. / Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. I: Nuclear Medicine Communications. 2009 ; Bind 30, Nr. 1. s. 30-6.
@article{cc9aea500f2711dfaefb000ea68e967b,
title = "Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer",
abstract = "OBJECTIVE: Breast cancer is one of the principal oncological challenges in the Western world. Currently, there are only a few reliable predictive methods for monitoring treatment. We investigated the ability of carbon-11 methionine ({"}11C-MET) positron emission tomography (PET) to evaluate early response to therapy in advanced breast cancer. METHODS: Thirteen patients with metastases in the lungs/pleura, lymph nodes, soft tissue, or bones entered a MET PET study both before and after the first cycle of polychemotherapy (n=4), or after the first month of therapy with hormones (n=5), or low dose weekly cytostatics (n=3). One patient underwent three PET studies: before hormonal therapy, after 1 month of hormonal therapy, and after the first cycle of polychemotherapy (total, 27 studies). MET accumulation in the metastatic sites was measured as standardized uptake values (SUVs), and the pretreatment and post-treatment SUVs were compared with each other and the clinical follow-up data. RESULTS: A total of 26 different metastatic sites were investigated in 13 patients. All metastases were visible by MET PET except one superficially spreading local skin recurrence, probably because of respiratory movements. Five new metastatic sites were detected. After therapy the SUVs decreased significantly (30-54{\%}; P < 0.05) in all six responding metastatic sites, whereas the SUVs of nonresponding metastases decreased somewhat (11-130/{\%}; n=4), remained stable (+/- 8{\%}; n=10), or increased (13-23{\%}; n=4) (P=NS). The SUVs of two nonresponding metastatic sites decreased clearly. Physiological MET uptake in the salivary glands, the myocardium, and the bone marrow did not disturb the image interpretation. CONCLUSION: MET PET may be useful in assessing the early response to therapy in advanced breast cancer.",
author = "Paula Lindholm and Maria Lapela and Kjell N{\aa}gren and Pertti Lehikoinen and Heikki Minn and Sirkku Jyrkki{\"o}",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "30",
pages = "30--6",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

Lindholm, P, Lapela, M, Någren, K, Lehikoinen, P, Minn, H & Jyrkkiö, S 2009, 'Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer', Nuclear Medicine Communications, bind 30, nr. 1, s. 30-6.

Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. / Lindholm, Paula; Lapela, Maria; Någren, Kjell; Lehikoinen, Pertti; Minn, Heikki; Jyrkkiö, Sirkku.

I: Nuclear Medicine Communications, Bind 30, Nr. 1, 01.01.2009, s. 30-6.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer

AU - Lindholm, Paula

AU - Lapela, Maria

AU - Någren, Kjell

AU - Lehikoinen, Pertti

AU - Minn, Heikki

AU - Jyrkkiö, Sirkku

PY - 2009/1/1

Y1 - 2009/1/1

N2 - OBJECTIVE: Breast cancer is one of the principal oncological challenges in the Western world. Currently, there are only a few reliable predictive methods for monitoring treatment. We investigated the ability of carbon-11 methionine ("11C-MET) positron emission tomography (PET) to evaluate early response to therapy in advanced breast cancer. METHODS: Thirteen patients with metastases in the lungs/pleura, lymph nodes, soft tissue, or bones entered a MET PET study both before and after the first cycle of polychemotherapy (n=4), or after the first month of therapy with hormones (n=5), or low dose weekly cytostatics (n=3). One patient underwent three PET studies: before hormonal therapy, after 1 month of hormonal therapy, and after the first cycle of polychemotherapy (total, 27 studies). MET accumulation in the metastatic sites was measured as standardized uptake values (SUVs), and the pretreatment and post-treatment SUVs were compared with each other and the clinical follow-up data. RESULTS: A total of 26 different metastatic sites were investigated in 13 patients. All metastases were visible by MET PET except one superficially spreading local skin recurrence, probably because of respiratory movements. Five new metastatic sites were detected. After therapy the SUVs decreased significantly (30-54%; P < 0.05) in all six responding metastatic sites, whereas the SUVs of nonresponding metastases decreased somewhat (11-130/%; n=4), remained stable (+/- 8%; n=10), or increased (13-23%; n=4) (P=NS). The SUVs of two nonresponding metastatic sites decreased clearly. Physiological MET uptake in the salivary glands, the myocardium, and the bone marrow did not disturb the image interpretation. CONCLUSION: MET PET may be useful in assessing the early response to therapy in advanced breast cancer.

AB - OBJECTIVE: Breast cancer is one of the principal oncological challenges in the Western world. Currently, there are only a few reliable predictive methods for monitoring treatment. We investigated the ability of carbon-11 methionine ("11C-MET) positron emission tomography (PET) to evaluate early response to therapy in advanced breast cancer. METHODS: Thirteen patients with metastases in the lungs/pleura, lymph nodes, soft tissue, or bones entered a MET PET study both before and after the first cycle of polychemotherapy (n=4), or after the first month of therapy with hormones (n=5), or low dose weekly cytostatics (n=3). One patient underwent three PET studies: before hormonal therapy, after 1 month of hormonal therapy, and after the first cycle of polychemotherapy (total, 27 studies). MET accumulation in the metastatic sites was measured as standardized uptake values (SUVs), and the pretreatment and post-treatment SUVs were compared with each other and the clinical follow-up data. RESULTS: A total of 26 different metastatic sites were investigated in 13 patients. All metastases were visible by MET PET except one superficially spreading local skin recurrence, probably because of respiratory movements. Five new metastatic sites were detected. After therapy the SUVs decreased significantly (30-54%; P < 0.05) in all six responding metastatic sites, whereas the SUVs of nonresponding metastases decreased somewhat (11-130/%; n=4), remained stable (+/- 8%; n=10), or increased (13-23%; n=4) (P=NS). The SUVs of two nonresponding metastatic sites decreased clearly. Physiological MET uptake in the salivary glands, the myocardium, and the bone marrow did not disturb the image interpretation. CONCLUSION: MET PET may be useful in assessing the early response to therapy in advanced breast cancer.

M3 - Journal article

C2 - 19306512

VL - 30

SP - 30

EP - 36

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 1

ER -